Deventer, 5 January 2026 – 819 Capital Partners has acquired a significant minority participation in RiverD International. The investment, through 819 Evergreen Fund, is aimed at supporting RiverD’s long-term growth and development.

RiverD is a Dutch high-tech company developing and manufacturing advanced instruments for non-invasive molecular analysis of human skin and tissue using Raman spectroscopy. Its skin analysis technology enables real-time, reagentless measurement of skin tissue composition. RiverD’s other R&D-focus area is Raman-guided surgery based on fiber-optic technology.

The company’s solutions are used globally in medical and dermatological research, and cosmetic and pharmaceutical R&D.

RiverD was founded by Gerwin Puppels, who is widely regarded as one of the world’s leading experts in Raman spectroscopy and a pioneer in its application to biomedical research. As founder and CEO, he has been the driving force behind RiverD’s scientific vision, technological leadership, and international reputation.

The transaction reflects 819 Capital’s confidence in RiverD’s technology, market position, and long-term potential. Through the investment from the 819 Evergreen Fund, RiverD gains access to growth capital and strategic support to accelerate product development, international expansion, and further market adoption.